Secondary polycythemia

Summary

Secondary polycythemia (MONDO:0020115) is a disease. A subtype of polycythemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	secondary polycythemia
Mondo ID	MONDO:0020115
Orphanet	98428
ICD-10-CM	D75.1
NCIT	C27178
UMLS	C1318533
MedGen	231144
GARD	0019467
MedDRA	10036062
Is cancer (heuristic)	no

Also known as: secondary erythrocytosis · secondary polycythemia

Disease family

This is a subtype of polycythemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › bone marrow disorder › polycythemia › secondary polycythemia

Related subtypes (4): familial polycythemia, polycythemia neonatorum, acquired polycythemia, physiological polycythemia

Subtypes (2): congenital secondary polycythemia, acquired secondary polycythemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.